1. Introduction {#sec1}
===============

Mitochondrial respiratory chain disorders (MRCDs) are dysfunction of the oxidative phosphorylation. MRCD is the most frequently congenital metabolic disease. The frequency is 1/5000 births. Half of MRCD cases are diagnosed in the neonatal period \[[@B1]\]. MRCDs in the neonatal period are fatal and show severe syndromes that are derived from multiple organs. Therefore, it is difficult to diagnose MRCD in the neonatal period. These pathogeneses are still unclear \[[@B2]\].

Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory disorder in an uncontrolled and ineffective immune response. HLH occurs either as a primary form or as a secondary form \[[@B3]\]. MRCDs as a cause of secondary form HLH are very rare.

We could diagnose MRCD by measuring the activity of the mitochondrial respiratory chain enzyme. We encountered a preterm infant who had MRCD that might have caused HLH. In this paper, we discuss the way to diagnose MRCD and the correlation between MRCD and HLH.

2. Case Report {#sec2}
==============

A 39-year-old woman with no gestation and no parturition became pregnant by intracytoplasmic sperm injection. There was no family history of sudden death or consanguineous marriage. At 34 weeks and 4 days of gestation, fetal hydrops (pleural effusion, ascites, and subcutaneous edema) was recognized. The infant was delivered by emergency caesarean section due to a nonreassuring fetal status. The infant was intubated due to grunting and transferred to our NICU. Apgar scores were 7 (1 min)/9 (5 min). Her weight was 2264 g (appropriate for dates). Her muscle tone was low. Mild retractions with no murmur and no rale were recognized. Abdominal finding was the distention with hepatosplenomegaly. No abnormal findings existed. We show laboratory findings in [Table 1](#tab1){ref-type="table"}. Lactic acidosis had continued, and jaundice appeared within 24 hours of birth. Disseminated intravascular coagulation (DIC) was recognized. The ammonia, C-reactive protein, and ferritin levels increased. On day 1, we measured cytokines. The findings were the following: IL-6 level 1398.3 pg/mL, IL-8 21675.0 pg/mL, INF-*γ* 5\> pg/mL, and TNF-*α* 8.2 pg/mL. The findings showed hypercytokinemia. We performed an exchange transfusion three times (twice on day 1 and once on day 2) for the early onset jaundice. The patient had prolonged lactic acidosis, mild hyperammonemia, and liver failure that was similar to the presentation of Reye syndrome. Laboratory change, which is related to liver failure, is shown in [Figure 1(a)](#fig1){ref-type="fig"}. Neonatal mass screening by tandem mass spectrometry, amino acid analysis, and urine organic acid analysis showed normal findings. From the above results, we suspected mitochondrial disease and began to administer vitamin B1, vitamin B2, vitamin C, Carnitine, and Coenzyme Q10 on day 2. On day 5, in the blood, lactate was 39.0 mg/dL, and pyruvic acid was 1.16 mg/dL (lactate/pyruvic acid ratio of 33.2 \> 20). In the cerebral spinal fluid, lactate was 43.6 mg/dL, and pyruvic acid was 1.73 mg/dL (lactate/pyruvic acid ratio of 25.2 \> 20). These results were also suggesting that she was mitochondrial disease. Thrombocytopenia and anemia did not improve. Specifically, thrombocytopenia was severe, and the patient received continuous platelet transfusion ([Figure 1(b)](#fig1){ref-type="fig"}). On day 6, we performed bone marrow aspiration, because mitochondrial disease was not enough for explaining pathogenesis of thrombocytopenia. We recognized a large amount of hemophagocytic macrophages, and we could not detect any evidence of malignancy. She was afebrile. However, the splenomegaly continued from admission. Other examination findings were as follows: WBC 11.4 × 10^3^/*μ*L, Hb 7.9 g/dL, Plt 2.4 × 10^4^/*μ*L, fibrinogen 74 mg/dL, and soluble IL-2 receptor 3805 U/mL. Although we could not measure fasting triglycerides and NK cell activity, our case was diagnosed as hemophagocytic lymphohistiocytosis (HLH), because she had five criteria of Revised Diagnostic Guidelines for HLH \[[@B4]\]. We began to administer prednisolone (2 mg/kg/day) on day 6 and cyclosporine (1 mg/kg/day) on day 8 to treat HLH. We also administered immunoglobulin (500 mg/kg) on day 8. On day 10, the patient died due to uncontrollable HLH, and an autopsy was performed after parental consent was given to perform the autopsy on the whole body except for her brain.

We took samples from the liver, muscle, and heart, and they were preserved at −80°C. Activities of the mitochondrial respiratory chain complexes I, II, III, and IV were assayed as described previously \[[@B5]\]. In these assays, citrate synthase (CS) was used as a housekeeping mitochondrial enzyme marker. The percent ratio of complex I activity to CS activity was decreased in all tissues ([Table 2](#tab2){ref-type="table"}). We diagnosed MRCD (mitochondrial complex I deficiency) based on the diagnostic criteria given by Bernier et al. \[[@B6]\].

According to the results above, she was diagnosed as having MRCD with HLH. We could not detect an antecedent infection ([Table 3](#tab3){ref-type="table"}). Although the mutation of*PRF1* is the most common genetic mutation of primary HLH in Japan, she had no mutation of*PRF1*.

3. Discussion {#sec3}
=============

We determined two important clinical issues. First, it is useful to measure the activity of the mitochondrial respiratory chain enzyme for diagnosing MRCD. Second, MRCD, which has a severe clinical course, may be related to HLH.

The diagnostic criteria given by Bernier et al. is useful for diagnosing MRCD \[[@B6]\]. This diagnosis requires one of the following: enzymology, histology, functional assay, or molecular assay.

Enzymatic diagnosis of MRCD is achieved by the activity of the mitochondrial respiratory enzyme. We can accurately measure the activity of the mitochondrial respiratory chain enzyme, as we appropriately take a sample and immediately preserve it at −80°C \[[@B7]\]. We can determine the biological function of the mitochondria by measuring the activity of the mitochondrial respiratory chain enzyme. In histology, the fact that there are \>2% ragged red fibers in the skeletal muscle is necessary for diagnosis; however, ragged red fibers are not common in children. Functional assays require the culture of fibroblasts, which takes a few months. Molecular assays are sometimes difficult. Calvo et al. reported exome sequencing of 42 MRCD patients, and only 24% of these patients had mutations in genes that have previously been linked to disease. 31% of them had mutations in nuclear genes that had never been linked to disease. 45% of them did not have any mutations \[[@B8]\]. Kohda et al. reported a comprehensive genetic analysis about 142 childhood-onset MRCDs. It revealed that 40 patients (28.2%) did not have any mutation in nuclear gene, mitochondrial DNA, and chromosome \[[@B9]\].

HLH might be secondary to MRCD. However, it is possible that HLH causes MRCD. It is well known that tumor necrosis factor (TNF) injures mitochondria and induces reactive oxygen species (ROS) production \[[@B10]\]. In our case, TNF-*α* was not so high. Therefore, it is difficult to interpret our case as secondary mitochondrial dysfunction due to hyperexcretion of TNF-*α*. In animal models, when the mitochondrial complex I is inhibited, the mitochondrial ROS production increases \[[@B11], [@B12]\]. Weinberg et al. reported that inflammatory cytokines are activated by mitochondrial generated ROS \[[@B13]\]. Therefore, in our case, we hypothesize that mitochondrial complex I deficiency causes ROS production, and HLH is induced by hypercytokinemia following the ROS.

Half of MRCD cases are diagnosed in the neonatal period, and 35% of the patients were diagnosed as having lethal infantile mitochondrial disorders \[[@B1]\]. As the symptoms of MRCD are nonspecific, the diagnosis is sometimes difficult. Therefore, MRCD may be the cause of the cryptogenic neonatal deaths that have severe clinical courses. HLH may be related to MRCD, which has a severe clinical course.

Cases involving both MRCD and HLH are rare, and we have experienced only one case. We must inform neonatologists about MRCD, because onset of MRCD is during the neonatal period. Then a further study of MRCD should be conducted.

4. Conclusion {#sec4}
=============

We recommend that an assay of the mitochondrial respiratory chain enzyme should be performed if mitochondrial disease is suspected. MRCD may be related to the pathogenesis of secondary HLH.
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![(a) Clinical course which is related to liver dysfunction. This figure shows the laboratory findings that are related to liver function. In a few days after birth, severe liver failure with a dominant increase in unconjugated bilirubin was evident. After that, aspartate aminotransferase and alanine aminotransferase levels were decreased; on the other hand, conjugated bilirubin level was increased. (b) Clinical course while she was hospitalized. This figure shows the clinical course of the patient. Thrombocytopenia did not improve after continuous platelet transfusion. Administration of vitamin B1, vitamin B2, vitamin C, Carnitine, and Coenzyme Q10 is a supporting therapy for mitochondrial disease. ^*∗*^FFP: fresh frozen plasma. ^*∗∗*^RCC-LR: red cell concentrates-leukocyte reduced.](CRIPE2016-3932646.001){#fig1}

###### 

Laboratory findings on admission.

  --------------------------------------- ---------------------------- -------------------
  CBC                                     WBC                          25.3 × 10^3^/*μ*L
  Band                                    10%                          
  Seg                                     28.5%                        
  Lymph                                   47%                          
  Mono                                    11%                          
  Eosino                                  1.0%                         
  Baso                                    0%                           
  Blast                                   0%                           
  RBC                                     2.34 × 10^6^/*μ*L            
  *Hb*                                    *8.3 g/dL*                   
  Ht                                      25.1%                        
  *Plt*                                   *1.7 ×*10^4^ */μL*           
  Ret                                     54.1‰                        
                                                                       
  Coagulation                             PT                           37.1 sec
  **APTT**                                **110.7 sec**                
  *Fib*                                   *40 mg/dL*                   
  HPT                                     22.6%                        
  **FDP**                                 **25.1 ** ***μ*** **g/dL**   
  *AT3*                                   *8.8%*                       
                                                                       
  Biochemistry findings                   **T-Bil**                    **7.7 mg/dL**
  D-Bil                                   0.2 mg/dL                    
  AST                                     47 IU/L                      
  ALT                                     6 IU/L                       
  CK                                      69 IU/L                      
  BUN                                     7 mg/dL                      
  Cr                                      0.61 mg/dL                   
  Na                                      138 mmol/L                   
  K                                       4.2 mmol/L                   
  Cl                                      109 mmol/L                   
  Ca                                      9.3 mg/dL                    
  P                                       5.7 mg/dL                    
  TP                                      3.2 g/dL                     
  *ALB*                                   *2.0 g/dL*                   
  **NH** ~**3**~                          **156 ** ***μ*** **g/dL**    
  **Ferritin**                            **3701.9 ng/mL**             
  **CRP**                                 **1.23 mg/dL**               
                                                                       
  Blood type                              O Rh(+)                       
                                                                       
  Immunological                           *IgG*                        *333 mg/dL*
  IgA                                     0 mg/dL                      
  IgM                                     12 mg/dL                     
  Direct Coombs test                      (---)                        
                                                                       
  Peripheral smear                        Spherocytosis                (---)
  Elliptocytosis                          (---)                        
                                                                       
  Blood gas analysis (artery intubated)   pH                           7.340
  O~2~                                    154.3 mmHg                   
  CO~2~                                   24.5 mmHg                    
  *HCO* ~3~ ^−^                           *12.9 mmol/L*                
  *BE*                                    *−10.8 mmol/L*               
  **Lac**                                 **70.1 mg**/**dL**           
  **Anion gap**                           **16.1**                     
                                                                       
  Chromosomal test (G band)               46,XX                         
  --------------------------------------- ---------------------------- -------------------

This table shows all laboratory findings on admission.

Bold font: high; italic font: low.

###### 

Enzyme assay of the mitochondrial respiratory chain (I--IV).

###### 

\(a\) Liver

  \%                 Co I^*∗*^   Co II^*∗∗*^   Co III^*∗∗∗*^   Co IV^†^   CS^††^
  ------------------ ----------- ------------- --------------- ---------- --------
  Patient                                                                  
   % of normal       15          31            78              100        108
   CS ratio (%)      13          28            68              88          
   Co II ratio (%)   46                        242             252         

###### 

\(b\) Muscle

  \%                 Co I   Co II   Co II + III   Co III   Co IV   CS
  ------------------ ------ ------- ------------- -------- ------- ----
  Patient                                                           
   % of normal       17     54      57            51       35      63
   CS ratio (%)      26     86      89            83       52       
   Co II ratio (%)   30             100           94       57       

###### 

\(c\) Heart

  \%                 Co I   Co II   Co II + III   Co III   Co IV   CS
  ------------------ ------ ------- ------------- -------- ------- -----
  Patient                                                           
   % of normal       15     89      53            159      63      112
   CS ratio (%)      14     79      46            142      57       
   Co II ratio (%)   26             76            220      46       

This table shows the activity of the mitochondrial respiratory chain enzyme (I--IV) in the liver, muscle, and heart.

^*∗*^Co I: complex. ^*∗∗*^Co II: complex II. ^*∗∗∗*^Co III: complex III. ^†^Co IV: complex IV. ^††^CS: citrate synthase.

###### 

Laboratory findings about antecedent infection.

  ------------------------------------- ------------------------ ---
  Infection                             Blood                     
   Toxoplasma                           IgM (−)                  
   Parvovirus B19                       IgM (EIA) (−), PCR (−)   
   Rubella                              IgM (EIA) (−), PCR (−)   
   Herpes simplex virus                 IgM (EIA) (−), PCR (−)   
   Cytomegalovirus                      IgM (EIA) (−), PCR (−)   
   Epstein-Barr virus                   PCR (−)                  
  Urine                                                          
   Cytomegalovirus                      PCR (−)                  
   Primary isolation of virus (day 7)   (−)                      
  Feces  ·  throat                                               
   Primary isolation of virus (day 7)   (−)                      
  ------------------------------------- ------------------------ ---

This table shows the laboratory findings regarding antecedent infection. We took samples for primary isolation of virus on day 7. The other samples were taken on admission. All findings were negative.
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